3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
141
Lung Neoplasms
51
Pancreatic Neoplasms
30
Non-Squamous Non-Small Cell Lung Cancer
18
Neoplasms
15
Adenocarcinoma of Lung
14
Head and Neck Neoplasms
13
Glioblastoma
13
Gliosarcoma
12
Breast Neoplasms
11
Brain Neoplasms
11
Neoplasm Metastasis
9
Carcinoma, Hepatocellular
9
Adenocarcinoma, Bronchiolo-Alveolar
9
Squamous Cell Carcinoma of Head and Neck
8
Carcinoma, Squamous Cell
7
Carcinoma, Renal Cell
7
Astrocytoma
6
Oligodendroglioma
5
Carcinoma
5
Urinary Bladder Neoplasms
4
Liver Neoplasms
4
Glioma
4
Esophageal Neoplasms
4
Colorectal Neoplasms
4
Adenocarcinoma
4
Recurrence
3
Rectal Neoplasms
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
Erlotinib Hydrochloride
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA